구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | R-DXd (Raludotatug Deruxtecan, Raludotatug Deruxtecan (R-DXd)) Merck Sharp & Dohme LLC·Gastrointestinal Cancer 9 trials |
|---|---|
Overview Program | Raludotatug Deruxtecan (R-DXd) |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ADC |
Overview Target | Gastrointestinal Cancer |
Overview Indication | Gastrointestinal Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules.. The classical cadherin (CDH), claudin (CLDN) and nectin families of transmembrane-type adhesion molecules are located at adherens or tight junctions in epithelial cells but diffuse to the nonjunctional cell surface in solid tumors with epithelial-mesenchymal plasticity. Human/humanized antibody-dru… |
Clinical Safety signal | Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules.. The classical cadherin (CDH), claudin (CLDN) and nectin families of transmembrane-type adhesion molecules are located at adherens or tight junctions in epithelial cells but diffuse to the nonjunctional cell surface in solid tumors with epithelial-mesenchymal plasticity. Human/humanized antibody-dru… |
Clinical Result source | ClinicalTrials.gov NCT03248492 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03248492 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | R-DXd (Raludotatug Deruxtecan, Raludotatug Deruxtecan (R-DXd)) Merck Sharp & Dohme LLC·Gastrointestinal Cancer 9 trials |
|---|---|
Overview Program | Raludotatug Deruxtecan (R-DXd) |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ADC |
Overview Target | Gastrointestinal Cancer |
Overview Indication | Gastrointestinal Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules.. The classical cadherin (CDH), claudin (CLDN) and nectin families of transmembrane-type adhesion molecules are located at adherens or tight junctions in epithelial cells but diffuse to the nonjunctional cell surface in solid tumors with epithelial-mesenchymal plasticity. Human/humanized antibody-dru… |
Clinical Safety signal | Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules.. The classical cadherin (CDH), claudin (CLDN) and nectin families of transmembrane-type adhesion molecules are located at adherens or tight junctions in epithelial cells but diffuse to the nonjunctional cell surface in solid tumors with epithelial-mesenchymal plasticity. Human/humanized antibody-dru… |
Clinical Result source | ClinicalTrials.gov NCT03248492 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03248492 |
추천 비교
추천 비교